arrow
C

Carl E. Schotborgh

haga hospital
H指数:30
被引数:4,640

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial

经导管主动脉瓣植入术 (pro-tavi) 患者经皮冠状动脉介入治疗的延期: 一项研究者发起的多中心、开放标签、非劣效性、随机对照试验

2026-03-290
PRE
Complex all-comers and patients with diabetes and prediabetes treated with Xience Sierra everolimus-eluting stents: COASTLINE high-risk
2025-11-010
OA
Impact of diabetes on three-year outcome after coronary stenting in patients with polyvascular atherosclerotic disease – a secondary analysis of the randomized TWENTE trials

糖尿病对多血管动脉粥样硬化疾病患者冠状动脉支架术后三年结局的影响——TWENTE随机试验的二次分析

2025-07-060
PRE
Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: Rationale and design of the PRO-TAVI trial
2025-03-012
OAAI
Continuation versus Interruption of Oral Anticoagulation during TAVI
2025-01-301
PRE
Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome 2-Year Results of the BIOVASC Study

急性冠状动脉综合征完全多支血管血运重建的时机:BIOVASC研究的2年结果

2024-12-010
OAAI
Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial
2024-07-011
PRE
Timing of Complete Multivessel Revascularization in Patients Presenting With Non-ST-Segment Elevation Acute Coronary Syndrome

非ST段抬高急性冠状动脉综合征患者完全多支血管血运重建的时机

2024-03-016
OAAI
Acute Coronary Syndrome Subphenotypes Based on Repeated Biomarker Measurements in Relation to Long-Term Mortality Risk
2024-01-160
OAAI
Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial
2023-11-012
OA
Serially measured high-sensitivity cardiac troponin T, N-terminal-pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and growth differentiation factor 15 for risk assessment after acute coronary syndrome: the BIOMArCS cohort
2023-04-252
OAAI
Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial
LANCET
IF88.5
2023-04-0176
PRE
Risk of bleeding after percutaneous coronary intervention and its impact on further adverse events in clinical trial participants with comorbid peripheral arterial disease
2023-03-014
OAAI
Final 5-Year Report of the Randomized BIO-RESORT Trial Comparing 3 Contemporary Drug-Eluting Stents in All-Comers
2022-11-1517
OAAI
Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trials
2022-08-018
OAAI